ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 2510 • ACR Convergence 2025

    Impact of ANCA specificity on risk of severe infection occurrence in ANCA-associated vasculitis.

    Clara Rouane1, Jon Idoate1, Morgane Mourguet1, Thomas Villeneuve1, Grégoire Prevot1, Laurent Guilleminault2, Stan Faguer1, Antoine Huart1, David Ribes1, Dominique Chauveau1, Martin Michaud1, Laurent Sailler1, Sébastien De Almeida Chaves1, Emmanuelle Mouchon1, Guillaume De Bonnecaze1, Margaux Lafaurie1, Guillaume Moulis1 and Grégory Pugnet3, 1CHU Toulouse, Toulouse, France, 2CHU Toulouse, Toulouse University, Toulouse, France, 3CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France

    Background/Purpose: ANCA specificity has shown an association with patients’ genetic profile, cytokine profile, certain clinical presentations, serologic response to treatment, and risk of recurrence.Severe infections…
  • Abstract Number: 1624 • ACR Convergence 2025

    Disease activity status in Takayasu’s arteritis influences the angiogenic potential of patient-derived endothelial cells

    Luciana Yamamoto de Almeida1, Kaitlin Quinn2, James Simone2, Lily Dai2, Benjamin Turturice2, Urvashi Kaundal2, Chloe Palmer2, Karyssa Stonick3, davide Randazzo4, Carmelo Carmona-Rivera5 and Peter Grayson6, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, 5Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, 6National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

    Background/Purpose: Takayasu's arteritis (TAK) is a rare, systemic, chronic large vessel vasculitis of unknown etiology primarily affecting the aorta and its branches. Arterial damage, with…
  • Abstract Number: 1147 • ACR Convergence 2025

    Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes

    Akhila Arya Perumangote Vasudevan1, Vishnu Mulavini2, Rasiya Hashim3, Madhumitha Rondla4 and Dileep C Unnikrishnan5, 1Yale University/Bridgeport Hospital, Stratford, CT, 2Calicut Medical College, Stratford, 3Franciscan Health Olympia & Chicago Heights, [email protected], IL, 4Texas tech university health sciences center, El paso, El Paso, TX, 5Bridgeport Hospital, Stratford, CT

    Background/Purpose: VEXAS syndrome is a recently described, adult-onset autoinflammatory disease caused by somatic mutations in the UBA1 gene, typically affecting hematopoietic stem cells. Renal involvement…
  • Abstract Number: 0759 • ACR Convergence 2025

    Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study

    Sehreen Mumtaz1, Lerone Clark2, Archit Srivastava2, Hannah Langenfeld3, Andrew C. Hanson3, Cynthia Crowson4, Andy Abril2, Nouran Eshak5, Megan Sullivan6, Matthew Koster3 and Kenneth Warrington3, 1Mayo Clinic Florida, Jacksonville, FL, 2Mayo Clinic, Florida, Jacksonville, FL, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Stewartvillle, MN, 5Mayo Clinic, Arizona, Scottsdale, AZ, 6Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Giant cell arteritis (GCA) is clinically heterogenous, and the presenting manifestations may influence diagnostic testing. The aim of this study was to evaluate the…
  • Abstract Number: 0730 • ACR Convergence 2025

    Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort

    Victor Pimentel-Quiroz1, Alvaro Oyarce-Calderón2, Allison Figueroa-Sánchez3, Leonor León-Yaurimucha3, Rocío Gamboa-Cárdenas4, Zoila Rodríguez-Bellido5, Risto Perich-Campos6, Graciela Alarcón7 and Manuel Ugarte-Gil8, 1Universidad Científica del Sur, San Isidro, Peru, 2Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, 3Universidad Científica del Sur, Lima, Peru, 4Universidad Científica del Sur, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, 6Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, 7The University of Alabama at Birmingham, Oakland, CA, 8Universidad Cientifica del Sur, Lima, Peru

    Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…
  • Abstract Number: 2700 • ACR Convergence 2025

    Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome

    Chloe Palmer1, Gustaf Wigerblad2, Tom Hill3, Benjamin Turturice1, Urvashi Kaundal1, Paul Schaughency3, Bhavisha Patel4, Emma Groarke5, Neal Young5, Stefania Dell'orso1 and Peter Grayson6, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institutes of Health, Stockholm, Sweden, 3NIAID, NIH, Bethesda, MD, 4National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, 5National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, 6National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

    Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe adult-onset inflammatory disease caused by somatic mutations of the ubiquitin-like modifier activating enzyme…
  • Abstract Number: 2504 • ACR Convergence 2025

    Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021

    Anuya Natu1, Isadora Small2, Shilpa Arora3 and Augustine Manadan4, 1John H Stroger, Jr. Hospital of Cook County, Chicago, IL, 2The Latin School of Chicago, Chicago, IL, 3Cook County Hospital, Chicago, IL, 4Rush University Medical Center, Chicago, IL

    Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis that can lead to significant morbidity and mortality. This study aims to evaluate the…
  • Abstract Number: 1623 • ACR Convergence 2025

    The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis

    Katarina Kmetova1, Gavin Poppei2, Kavya Sugur3, Julia Ford4, Wenying Liang4, Emily Chong4, Srilakshmi Yalavarthi4, NaveenKumar Somanathapura4, Nataliya Milman5, Peter Merkel6, Ora Singer7 and Yu (Ray) Zuo4, 1Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 2University of Michigan, Ann arbor, 3Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, 4University of Michigan, Ann Arbor, MI, 5the Ottawa Hospital, Ottawa, ON, Canada, 6University of Pennsylvania, Philadelphia, PA, 7University of Michigan, Huntington Woods, MI

    Background/Purpose: Clinically-isolated aortitis (CIA), defined as inflammation of the aortic wall in the absence of extra-aortic arterial involvement, systemic vasculitis, or other associated autoimmune disease,…
  • Abstract Number: 1075 • ACR Convergence 2025

    Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study

    Michael Hamilton1, Justin Riley Lam2, Emmanuel Otabor3, Laith Alomari3, Maxim Barnett3, Fabian Rodriguez Quinonez4 and Irene Tan5, 1Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, 2Jefferson Einstein Hospital, Philadelphia, PA, 3Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, 4Einstein Medical Center Philadelphia, Philadelphia, PA, 5Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA

    Background/Purpose: Giant-cell arteritis (GCA) is usually described in people of Northern-European ancestry, and little is known about outcomes in Black and Hispanic (B-His) patients. Using…
  • Abstract Number: 0758 • ACR Convergence 2025

    Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis

    Raquel Ugena-García1, Clara Churtichaga Domenech2, Judith Vidal-Ripoll2, Francina salabert-Carreras2, Cristina Calomarde-Gómez1, Cristina Rocamora-Gisbert3, Irene Peralta-García4, Niccolo Viveros2, Anne Riveros Frutos3, Ivette Casafont-Solé1 and Judit Font-Urgelles1, 1Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Germans Trias i Pujol, Barcelona, 3Hospital Germans Trias i Pujol, Barcelona, Spain, 4Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in patients over the age of 50. Interleukin-6 (IL-6) has been shown to…
  • Abstract Number: 0727 • ACR Convergence 2025

    Higher rates of severe sensorineural hearing loss in granulomatosis with polyangiitis (GPA) compared to other antineutrophil cytoplasmic antibody (ANCA) associated vasculitis

    Sehreen Mumtaz1, Kindalem Fentie2, Joseph Parker2, Emily Craver1, Vikas Majithia3 and Andy Abril4, 1Mayo Clinic Florida, Jacksonville, FL, 2Mayo Clinic, Florida, Jacksonville, FL, 3Mayo Clinic Hospital, Jacksonville, FL, 4Mayo Clinic Florida, Jacksonville

    Background/Purpose: Hearing loss in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is one of the commonly reported manifestations of organ damage in AAV with predominantly…
  • Abstract Number: 2610 • ACR Convergence 2025

    Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy

    Adrian Martin-Gutierrez1, Javier Loricera2, Diana Prieto-Peña3, Vicente Aldasoro Cáceres4, Olga Maiz5, Eugenio de Miguel6, Eva Galíndez Agirregoikoa7, Ivan Ferraz Amaro8, Santos Castañeda9 and Ricardo Blanco10, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, 4Hospital Universitario de Navarra, Pamplona, Spain, 5Hospital Universitario de Donosti, Donostia, Spain, 6Hospital Universitario La Paz, Madrid, Spain, 7BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 8Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 9Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 10Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Aortitis is a frequent and potential severe complication of giant cell arteritis (GCA)(GCA-aortitis). Tocilizumab (TCZ) was approved for the treatment of GCA, but its…
  • Abstract Number: 2218 • ACR Convergence 2025

    Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study

    Edgar Iván Mendoza Ríos, María Del Carmen Zamora Medina, Mario Isaac Lumbreras Márquez, Diana Yazmin Copado mendoza, Oralia Alejandra Orozco Guillén, Maria José rodríguez Sibaja, Martha Leticia Palafox Vargas and Sandra Acevedo gallegos, Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico

    Background/Purpose: IgA vasculitis (IgA-V) is a systemic vasculitis involving small vessels, most frequently affecting children. There is few information about pregnancy outcomes in women with…
  • Abstract Number: 1621 • ACR Convergence 2025

    Temporal Association Between Viral Positivity Rates and Kawasaki Disease Incidence at a Large Tertiary Center

    Jessica Nguyen1, Duc Nguyen1, Ankona Banerjee2, Kenneth Nobleza2, Denver Niles2 and Marietta De Guzman1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston

    Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis associated with the development of coronary artery aneurysms predominantly affecting children less than 5 years of age.…
  • Abstract Number: 1074 • ACR Convergence 2025

    Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis

    Michael Hamilton1, Justin Riley Lam2, Emmanuel Otabor3, Laith Alomari3, Maxim Barnett3, Shahrzad Abdollahi2 and Irene Tan4, 1Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, 2Jefferson Einstein Hospital, Philadelphia, PA, 3Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, 4Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA

    Background/Purpose: Racial/ethnic disparities in Behçet’s disease (BD) outcomes are largely undocumented in the United States. Given known differences in disease expression across populations globally, we…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 41
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology